Literature DB >> 11067925

Antagonism of direct alloreactivity of an HLA-B27-specific CTL clone by altered peptide ligands of its natural epitope.

M García-Peydró1, A Paradela, J P Albar, J A Castro.   

Abstract

Antagonism of allospecific CTL by altered MHC ligands is a potential approach to specific immunomodulation of allogeneic T cell responses in acute graft rejection and graft-vs-host disease. In this study we have analyzed the capacity of peptide analogs of a natural HLA-B27-allospecific CTL epitope to antagonize direct alloreactivity. Alanine scanning demonstrated that positions 4, 5, and 7 of the peptide epitope were critical for allorecognition. A number of relatively conservative substitutions at each of these positions were then tested for their effect on allorecognition and antagonism. All substitutions at position 5 abrogated cytotoxicity. In contrast, a few changes at positions 4 and 7 were tolerated, indicating a limited flexibility of the allospecific CTL in recognition of peptide epitope variants. Most of the substitutions impairing cytotoxicity actually induced antagonism. However, whereas epitope variants with changes at positions 4 and 7 behaved as weak or intermediate antagonists, some of the variants with changes at position 5 antagonized CTL alloreactivity almost completely. The results in this study demonstrate for the first time that antagonism of direct class I-mediated alloreactivity can be achieved by variants of a natural allospecific peptide epitope.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11067925     DOI: 10.4049/jimmunol.165.10.5680

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene.

Authors:  Annika C Karlsson; Steven G Deeks; Jason D Barbour; Brandon D Heiken; Sophie R Younger; Rebecca Hoh; Meghan Lane; Matti Sällberg; Gabriel M Ortiz; James F Demarest; Teri Liegler; Robert M Grant; Jeffrey N Martin; Douglas F Nixon
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.

Authors:  Zinal S Chheda; Gary Kohanbash; Kaori Okada; Naznin Jahan; John Sidney; Matteo Pecoraro; Xinbo Yang; Diego A Carrera; Kira M Downey; Shruti Shrivastav; Shuming Liu; Yi Lin; Chetana Lagisetti; Pavlina Chuntova; Payal B Watchmaker; Sabine Mueller; Ian F Pollack; Raja Rajalingam; Angel M Carcaboso; Matthias Mann; Alessandro Sette; K Christopher Garcia; Yafei Hou; Hideho Okada
Journal:  J Exp Med       Date:  2017-12-04       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.